Pacira BioSciences, Inc. Common Stock

PCRXNASDAQUSD
24.51 USD
0.85 (3.35%)AT CLOSE (11:59 AM EDT)
24.92
0.41 (1.65%)
POST MARKET (AS OF 06:10 PM EDT)
Post Market
AS OF 06:10 PM EDT
24.92
0.41 (1.65%)
🔴Market: CLOSED
Open?$25.39
High?$25.43
Low?$24.22
Prev. Close?$25.36
Volume?525.9K
Avg. Volume?627.0K
VWAP?$24.64
Rel. Volume?0.84x
Bid / Ask
Bid?$24.40 × 100
Ask?$24.54 × 100
Spread?$0.14
Midpoint?$24.47
Valuation & Ratios
Market Cap?992.4M
Shares Out?40.5M
Float?40.5M
Float %?94.2%
P/E Ratio?141.09
P/B Ratio?1.43
EPS?$0.17
Dividend?0.00%
Ex-Dividend?N/A
Technical Outlook
Loading...
Fundamental Outlook
Loading...
Short Interest
Loading...
Financial Health
Current Ratio?4.54Strong
Quick Ratio?3.28Strong
Cash Ratio?1.31Strong
Debt/Equity?0.54Moderate
ValuationATTRACTIVELY VALUED
Score
89/100
P/E?
141.1PRICEY
P/B?
1.43CHEAP
P/S?
1.37CHEAP
P/FCF?
7.3CHEAP
EV/EBITDA?
10.9CHEAP
EV/Sales?
1.66CHEAP
Returns & Efficiency
ROE?
1.0%WEAK
ROA?
0.6%WEAK
Cash Flow & Enterprise
FCF?$136.7M
Enterprise Value?$1.2B
Fundamentals ratios updated end of day
xxx
Related Companies
Loading...
News
Profile
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
Employees
829
Market Cap
992.4M
Industry
PHARMACEUTICAL PREPARATIONS
Listed
2011-02-03
Address
2000 SIERRA POINT PARKWAY
BRISBANE, CA 94005
Phone: 650-242-8052